Product Information
RESTASIS MULTIDOSE 0.05% EYE is a brand product labeled by Allergan, Inc., priced at $112.3216 per ML under NDC 00023530105. Its NADAC has been published 490 times since May 17, 2017.
FDA first approved this application on Dec 23, 2002. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the cyclosporine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
.5 mg/mL
Manufacturer
Allergan, Inc.NDC
00023530105
Classification
Brand
Dosage Form
EMULSION
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
CYCLOSPORINEApproval Type
New Drug (NDA)
FDA Application
NDA050790FDA Approved
12/23/2002
TE Code
AB
On Market Since
11/10/2016
Pharmacological Classes
Price Statistics
The NADAC for RESTASIS MULTIDOSE 0.05% EYE has been published 490 times since May 17, 2017, and over the history we have for it it has risen 39.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $112.3216 per ML |
|---|---|
| All-time high | $112.6932 (Oct 12, 2022) |
| All-time low | $80.4772 (May 17, 2017) |
| 52-week high | $112.4473 |
| 52-week low | $112.3161 |
| Median price | $107.3279 |
| Average price | $104.3710 |
| Largest weekly change | +9.5% (Jan 9, 2019) |
| Weeks tracked | 490 |
| Tracking since | May 17, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the cyclosporine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Allergan, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
cyclosporine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcineurin Inhibitor Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RESTASIS MULTIDOSE 0.05% EYE?
The current National Average Drug Acquisition Cost (NADAC) for RESTASIS MULTIDOSE 0.05% EYE, manufactured by Allergan, Inc., is $112.3216 per ML (NDC 00023530105), effective Sep 30, 2026.
How has the price of RESTASIS MULTIDOSE 0.05% EYE changed over time?
Over the history we have for it, the NADAC for RESTASIS MULTIDOSE 0.05% EYE has risen 39.6%. It has been tracked across 490 weekly CMS publications since May 17, 2017.
What are the highest and lowest recorded NADAC prices for RESTASIS MULTIDOSE 0.05% EYE?
Since May 17, 2017, the NADAC for RESTASIS MULTIDOSE 0.05% EYE has ranged from a low of $80.4772 (May 17, 2017) to a high of $112.6932 (Oct 12, 2022), with a median of $107.3279 per ML.
Are there cheaper alternatives to RESTASIS MULTIDOSE 0.05% EYE?
No other NADAC-published product currently shares the active ingredient and strength of RESTASIS MULTIDOSE 0.05% EYE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RESTASIS MULTIDOSE 0.05% EYE?
RESTASIS MULTIDOSE 0.05% EYE (NDC 00023530105) is labeled by Allergan, Inc., and CMS classifies it as a brand product.